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Abstract 
Tissue microarray (TMA) is a well-established technique that connects basic research 
with clinical applications that allow the validation of many pathobiologic events from 
gene expression dysregulation to genomic aberrations. However, conventional TMAs 
have several limitations such as limited representation of tissue heterogeneity, 
destruction of donor tissue blocks due to coring and usage of particular specimens that 
have limited evaluable material (tissue from thin specimens or needle biopsies).  We 
have developed a novel method, which we termed “Spiral TMA” that generates TMAs 
that allow for improved representation of the donor tissue while keeping the 
architectural details of the donor block intact. This technology is ideal for specimens 
with limited tissue without the need to punch holes into the original block and therefore 
preserving the tissue integrity. In this report, we describe the methodology of 
constructing Spiral TMA and demonstrate the validation of tumor representation and 
tissue heterogeneity by comparing Spiral TMA to conventional TMA using 
immunohistochemical staining to EGFR and CK7. 
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Introduction 
 
Since its description by Kononen et al1, tissue microarrays (TMAs) have emerged as a 
well-established technique connecting basic research to clinical applications that have 
become important as a translational research tool. They have proven to be an effective 
way to provide high-throughput analysis of hundreds of tissue specimens in a single 
slide while keeping uniform experimental conditions and being cost effective as tissue 
samples from multiple patients are processed in an identical manner at the same time. 
TMAs have allowed the identification and validation of the functional and clinical 
significance of physiologic and pathobiologic events regarding gene expression 
dysregulation, genomic aberrations, and epigenetic phenomena by exploring the 
correlations between molecular information and clinico-pathological features 2-6. 
However, conventional TMAs (CTMAs) have several drawbacks. One pertinent 
criticism has been that the tissue analyzed on a TMA is not representative of the entire 
original tissue specimen. This is of special importance in tumors with heterogeneous 
morphology that have multiple growth patterns such as mixed germ cell tumors with 
heterogenous histological component that have various staining patterns, or lung 
adenocarcinomas with mixed histology7.  
CTMA blocks are constructed by punching tissue cores in “donor” blocks and 
transferring them into a “recipient” block. The donor blocks require sufficient amount of 
tissue, and many surgical pathology specimens especially from biopsies with limited 
material may not be suitable for CTMA construction allowing for exclusion from 
investigational studies and further selection bias. This is especially noteworthy because 
biopsy specimens may represent the only sample that was collected from patients with 
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advanced cancer prior to neo-adjuvant treatment. Lastly, punching of the paraffin donor 
blocks inevitably leaves at least one hole in each tissue donor block. This bears 
considerable significance since interesting or rare tissue samples archived in many 
institutions may often get exhausted and therefore it is difficult to study cored tissues as 
part of a multi-center collaboration. 
To improve the limitations of CTMAs, we have now developed a novel 
approach, which we termed “Spiral tissue microarray” (STMA), in which each TMA 
core consists of a reeled layer of tissue cut as a horizontal section from the donor block 
and not punched as a vertical cylinder core. With this method, it is possible to construct 
microarrays from tissue as thin as 20 μm without damaging the donor paraffin block 
(Fig. 1).  In addition, since the whole section is represented on the STMA, sampling 
bias due to tissue heterogeneity is greatly reduced. Here, we describe in detail the 
construction of STMA and the validation for research use specifically focusing on 
reducing sampling bias due to tumor heterogeneity. 
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Results: 
Our study cohort consisted of 25 archival paraffin blocks from pulmonary 
adenocarcinoma patients as described in detail in the Methods section. Morphologic 
integrity, quality, and tissue representation were verified by hematoxylin and eosin 
(H&E) stained sections compared to the adjacent H&E stained sections of the original 
donor blocks. As demonstrated in Fig. 2, our array contained 25 cores of reeled tissue 
(Panel a), each reel representing an entire longitudinal plane of the donor block. All 25 
cores contained expected amount of tumor tissue with/without surrounding normal lung 
tissue where histological findings were identical to H&E staining in the adjacent section 
of the original blocks (Fig. 2, Panels b and c). Although histological architecture is 
inevitably lost to a certain degree compared to standard sections, the underlying 
composition of the tumor in regards to tumor cellularity and architectural detail are 
clearly recognizable (Fig. 2, Panel c). 
 In addition, we compared the staining of immunohistochemical markers EGFR 
and CK7 between CTMA and STMA. We used pulmonary adenocarcinomas because of 
their vast tissue heterogeneity8. It is well known that more than 90% of lung 
adenocarcinomas represent a mixture of various architectural subtypes. In addition, we 
noticed intra-tumoral differences in immunostaining intensity as a reflection of staining 
heterogeneity. For each tumor we computed an immunostaining intensity score (IS) 
difference as the largest variation in staining intensity. Among the 25 cases analyzed in 
CTMA, EGFR expression was diffuse and homogeneous in 22 cores and CK 7 
expression in 18 cores, respectively. Among the 25 cases analyzed in STMA, EGFR 
expression was diffuse and homogeneous in 14 reels and CK 7 in 6 reels, respectively. 
In CTMA IS differences of 1 were detected for EGFR in 3 cores and for CK7 in 7 cores. 
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In STMA IS differences of 1 were detected for EGFR in 8 cores and for CK7 in 10 
cores. There was no core in CTMA showing IS differences of 2 for either EGFR or CK7, 
whereas 3 and 9 reels were found to have IS difference of 2 for EGFR and CK7, 
respectively in STMA. The range of the staining intensity, expressed by subtraction of 
minimum IS from maximum IS, was significantly increased in STMA than CTMA in 
both EGFR and CK7 (P< .01 for both) (Fig. 3, Panel a-c). Of note, in the STMA, the 
mean size of each tissue fragment is 1.44mm2 (range 1.0 to 2.04 mm2), while in a 
CTMA is 3.14mm2. 
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Discussion:  
 Our results show that we can achieve an improved representation of multiple 
areas in a tumor while still maintaining the advantages of the array technology such as 
high-throughput, experimental uniformity, and cost-effectiveness 1,9.  This eliminates 
the selection bias as well. Since STMA uses only one planar tissue section, blocks with 
little remaining tissue that cannot be used for CTMAs can be included in studies. 
Furthermore, many core needle biopsy samples, such as transrectal prostate biopsy 
specimens or breast biopsy which cannot be routinely used for TMA construction with 
conventional approaches are amenable to the STMA technique. As the tissue is too thin 
to be sampled vertically, it has insufficient depth to be sampled for a TMA. These 
biopsy specimens are however ideal to be arrayed with STMA technology as the entire 
biopsy can be represented in a reel on the array (see Supplementary Fig.1). The clinical 
implication for the evaluation of diagnostic and prognostic biomarkers on such needle 
biopsy specimens can be substantially improved. 
Recently, there are a few reports describing the clinical application of CTMA to 
evaluate biomarkers for breast cancer 10,11. In these reports, high agreement of 
expression of HER2 and estrogen and progesterone receptors between cored breast 
cancer TMA and standard tissue section using immunohistochemical analysis are 
demonstrated and it is suggested that the routine use of TMA technique for biomarker 
evaluation may be applicable. Our method allows for maintaining the donor tissue block 
integrity as well as facilitating the collection of tissue samples, which will promote 
inter-institutional collaborations and ideally clinical applications.  
We believe that validating prospective diagnostic or prognostic markers on 
STMA in combination with CTMAs may facilitate and accelerate biomarker discovery. 
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Another advantage of our approach is that sections that will be arrayed on a STMA are 
identical to the adjacent hematoxylin-eosin sections taken from the paraffin blocks. 
Therefore, the tissue that will be represented on the array can be validated. In CTMA on 
the contrary, there is increased variability since the original HE section only 
corresponds to the first few sections of the cores but not the deeper ones 12. We observed 
a greater range of immunostaining in STMA tissue fragments compared to CTMA 
fragments which indicates a greater representation of tissue heterogeneity in STMAs 
than in CTMAs. One potential limitation of STMAs may be the limited representation 
of tissue architecture compared to CTMA due to smaller tissue fragment size. However, 
we were able to show in this report that 100 μm-thick sections are representative of the 
entire tumor morphology. Increasing section thickness may enhance the tumor 
architectural detail if necessary. Increased tumor representation on STMA leads to 
increased space demands on the array block and therefore fewer samples can be arrayed. 
From our current experience, we estimate that an STMA can accommodate as many as 
50 cores in one paraffin block which is less than in a CTMA block. However, increased 
representation of tumor heterogeneity may alleviate the necessity to sample multiple 
cores of one donor block as is routinely done in CTMAs where about 600-800 cores are 
assembled from 200-300 patients.  
LeBaron et al also suggested a method to create TMA without coring the 
blocks 13. By their method, the spot for each case is a tiny square for which advantages 
of STMA described above cannot be applied.  
Other experimental and clinical applications commonly used for CTMA and 
better applicable for STMA are for tissue banking and for positive/negative controls of 
various antibodies used in the immunohistochemistry laboratory14. Since no special 
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device is required for the sectioning part, keeping a few additional thick sections for 
tissue banking and/or control array is an easy application in the routine clinical practice. 
In summary, we have developed a novel approach for tissue microarray 
construction, Spiral TMAs, which has several advantages to the conventional 
construction of TMAs while maintaining the advantages of high-throughput array 
technology. Specifically, 1) the increased representation of tissue heterogeneity, 2) the 
possibility to include small biopsy specimens and 3) the fact that donor tissue is 
sectioned and not destroyed by punching holes allows for the inclusion of surgical 
pathology specimens which has been previously not amenable to research due to limited 
material. Due to the new technique we are describing in the current study, STMA may 
expand the investigation of entirely new tissue repositories. We believe that STMA is 
another step in the evolution of high-density tissue microarrays and will further 
facilitate translational research that will enrich our knowledge and expand the 
information regarding molecular abnormalities in cancer. 
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Figures Legends: 
 
Figure 1. A schematic overview of Spiral Tissue Microarray (STMA) construction. 
Regions of interest are marked with sharpie pen directly on the block. 20 - 100 µm thick 
slices of the sample block are cut and rolled up into cylindrical reels. This cylindrical 
reel is divided into 2-3mm tall including marked regions of interest and transferred 
vertically into the recipient block/cassette with arranged 3.3 mm diameter holes. A 
STMA block can be then sectioned in the usual histopathologic fashion. 
 
Figure 2. Histological appearance of Spiral Tissue Microarray (STMA) 
(a-c) STMA holding 25 rolls of pulmonary adenocarcinoma.  Low-power 
magnification of STMA (H&E stain) (a).  Low power view of one representative reel 
in the STMA (b). Higher magnification indicates preserved morphology of the 
adenocarcinoma in the left side, and normal lung area in the right side (c).   
Scale bars in image a, b and c indicate 2.0mm, 0.5mm and 0.1mm, respectively.    
   
Figure 3. Comparison of tissue heterogeneity seen in conventional and Spiral 
TMAs.  
a-b) CK7 immunohistochemical staining in the conventional TMA (CTMA) (a) and 
Spiral TMA (STMA) (b). Both core and reel are taken from the same donor block. Note 
intensity score (IS) 3 (arrow) and IS 1 (arrow head) can be identified in the same reel in 
STMA while diffuse IS 3 staining is seen in the CTMA. Scale bars in both a) and b) 
indicate 0.5 mm.   
c) The difference of IS in the same core/reel, calculated by subtraction of minimum IS 
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from maximum IS, in CTMA and STMA. The shaded bars are for EGFR expression 
while gray and black bars are for CK7 expression. No differences of IS of EGFR and 
CK7 were found in the majority of cases (22 and 18 cases, respectively) in CTMA, 
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Supplementary Figure 1. 
 
(a-c) A reel of Spiral TMA created from the core needle biopsy of breast cancer patient.  
a) Lower magnification of the reel (H&E staining). Note three thin biopsied fragments 
are lined together in a roll shape.  b) Higher magnification of the same reel.  c) 
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Materials and Methods 
 
Construction of Spiral TMAs.  
STMA block holding 25 reeled cores of pulmonary adenocarcinoma cases.  
We selected 25 paraffin blocks holding pulmonary adenocarcinoma tissue 
larger than 1cm square from the pathology archive of Toyama University Hospital, 
Toyama, Japan. The blocks were heated around 40C on the surface, and 100 μm-thick 
sections were cut with a standard microtome. The tissue sections were manually rolled 
up into tissue reels. Each tissue reel was then cut into 3 mm-tall subcylindrical reel. 
Each subcylindrical reel was vertically embedded into plastic tissue-holding-cassette 
with 26 holes of 3.3 mm diameter (Azumaya Co. Ltd., Tokyo). Melted paraffin was 
pored into the cassette to re-embed the reeled tissue followed by cooling down. Lastly, 
the STMA block was sectioned at 4 µm. 
CTMA holding cores from same 25 blocks was also constructed to compare the 
degree of tissue heterogeneity coverage. Cores with two mm diameter were transferred 
to the same plastic cassette using manual tissue microarrayer (JF-2, Pathology Institute, 
Toyama). The cassette was re-embedded using same method as described previously. 
 
Immunohistochemical staining: 
 Anti EGFR and CK7 immunohistochemical staining was performed for 4 μm 
thick specimens of each block as described previously 6. Briefly, after sectioning and 
deparaffinization of sections, the specimens were heated up to 95C using a water-bath 
for 40 minutes in Tris/EDTA buffer at pH 9 (Target Retrieval Solution; DAKO). A 
DAKO autostainer was used for all immunohistochemical process (DAKO, Kyoto, 
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Japan). Clones and titrations of each antibody were as follows: EGFR (clone 
DAK-H1-WT, IgG1, titration 1:50, DAKO) and CK7 (clone OV-TL 12/30, DAKO, 
1:100). Envision+ system (DAKO) was used for the signal enhancement. The reaction 
products were visualized with DAB+ (DAKO). The nuclei were lightly counterstained 
with Mayer’s hematoxylin solution. All procedures were carried out at room 
temperature. 
 
Scoring of the staining results and statistical analysis  
Staining intensity (IS) was scored as 0 (no signal), 1 (weak signal), 2 (moderate 
signal) or 3 (marked signal) as previously reported 5,6.  To compare the heterogeneity 
covered by both TMA techniques, we scored maximum and minimum IS in the same 
core/reel. The range of the staining intensity, expressed by subtraction of minimum IS 
from maximum IS, was considered as the degree of covered heterogeneity. The range 
was scored in both STMA and CTMA using same 25 pulmonary adenocarcinoma cases. 
Mann-Whitney's U test was used for the statistical analysis to compare the differences 
of the two groups. P value less than 0.05 was considered significant. 
This study was approved by the Institutional Review Board of Toyama University 
Hospital (No.19-12, Toyama, Japan).
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